Federal Register / Vol. 77, No. 3 / Thursday, January 5, 2012 / Notices 509 

complete pre-/post-campaign 

questionnaires for non-smokers is 2,000. 

To obtain the target number of 

complete pre-/post-campaign responses, 

approximately 34,660 respondents will 

be contacted through an initial 

screening and consent process. The 

estimated burden per response is two 

minutes. 

An estimated 11,600 smokers will be 

recruited to complete the Smoker 

Baseline Questionnaire in order to yield 

5,000 completed post-campaign Smoker 

Follow-Up Questionnaires. An 

estimated 2,666 non-smokers will be 

recruited to complete the Non-smoker 

Baseline Questionnaire in order to yield 

2,000 completed post-campaign Nonsmoker Follow-up Questionnaires. For 

both respondent groups, the estimated 

burden per response is 25 minutes for 

each baseline questionnaire. In addition, 

the estimated burden per response is 25 

minutes for each post-campaign (followup) questionnaire. 

Data from this information collection 

will be used to estimate awareness of 

and exposure to The Campaign among 

smokers and non-smokers nationally as 

well as among the planned subset of 

smokers in high-delivery geographic 

areas for The Campaign. These estimates 

will take the form of self-reported ad 

recognition and recall estimates that 

assess basic exposure as well as 

frequency of ad exposure. Data from this 

information collection will also be used 

to examine statistical associations 

between exposure to The Campaign and 

pre-post changes in specific outcomes of 

interest which will include knowledge, 

attitudes, beliefs and intentions related 

to smoking and cessation as well as 

behavioral outcomes including quit 

attempts and cigarette consumption. 

OMB approval is requested for one 

year. There are no costs to respondents 

other than their time. The total 

estimated burden hours are 10,015. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

General Population ......................................... Screening and Consent Process ................... 34,660 1 2/60 

Adults, ages 18–54 in the U.S. ....................... Smoker Baseline Questionnaire .................... 11,600 1 25/60 

Smoker Follow-Up Questionnaire .................. 5,000 1 25/60 

Non-Smoker Baseline Questionnaire ............. 2,666 1 25/60 

Non-Smoker Follow-up Questionnaire ........... 2,000 1 25/60 

Dated: December 29, 2011. 

Daniel Holcomb, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2011–33799 Filed 1–4–12; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 PR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 76 FR 66308–66309, 

dated October 26, 2011) is amended to 

reflect the reorganization of the 

Financial Management Office within the 

Office of the Chief Operating Officer, 

Centers for Disease Control and 

Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: 

Delete items (1), (2) and (3) of the 

functional statements for the Financial 

Management Office (CAJE), and insert 

the following: (1) Provides leadership 

and coordination in the development 

and administration of the Centers for 

Disease Control and Prevention’s (CDC) 

financial management policies; (2) 

provides leadership and advice on 

matters of public health policy, budget 

formulation, budget and performance 

integration, and Congressional 

appropriations for CDC and the Agency 

for Toxic Substances and Disease 

Registry (ATSDR); (3) collaborates with 

the CDC Office of the Director (OD) in 

the development and implementation of 

long-range, strategic program and 

financial plans; 

Delete in its entirety the title and 

functional statements for the Travel 

Management Activity (CAJE12). 

Delete in its entirety the title and 

functional statements for the Office of 

Organizational Excellence (CAJE13) and 

the Office of Formulation, Evaluation, 

and Analysis (CAJE14) and insert the 

following: 

Office of Management Services 

(CAJE13). (1) Collaborates and 

maintains liaison with CDC 

management officials to monitor and 

address priority issues of concern to 

CDC leadership; (2) manages the 

Financial Management Office’s (FMO) 

operational budget processes, including 

planning, execution, and monitoring; (3) 

manages FMO’s acquisition processes; 

(4) analyzes and provides 

recommendations on workload 

efficiency and resource utilization; (5) 

provides direction, strategy, analysis, 

operational support, and 

recommendations in matters concerning 

organizational performance and 

management services within FMO; (6) 

coordinates the development of, and 

maintains, strategic management and 

performance measurement tools within 

FMO; (7) monitors FMO organizational 

performance and provides 

recommendations on performance 

improvement; (8) provides management, 

oversight, and administrative support 

for FMO service desk operations; (9) 

provides direction, strategy, analysis, 

and operational support in all aspects of 

FMO’s human resources operations; (10) 

provides leading practices in 

government financial management 

practices to FMO; (11) develops, 

implements, and manages recruiting, 

hiring, retention, and succession 

strategies; (12) coordinates creation and 

implementation of operating standards/ 

procedures and processes, and monitors 

compliance; (13) develops, implements, 

and manages professional development 

strategy and plan for FMO; (14) 

develops and implements FMO’s 

communication strategy and plan; (15) 

manages the development and 

communication of financial 

management policies; (16) serves as 

FMO’s point of contact on all matters 

concerning facilities management and 

space utilization; and (17) serves as 

FMO’s coordinator of COOP activities. 

Appropriations, Legislation, and 

Formulation Office (CAJE14). (1) 


emcdonald on DSK5VPTVN1PROD with NOTICES
510 Federal Register / Vol. 77, No. 3 / Thursday, January 5, 2012 / Notices 

Provides leadership, consultation, 

guidance, and advice on matters of 

public health and financial policy; (2) 

leads all CDC/ATSDR Congressional 

appropriations activities; (3) develops 

CDC/ATSDR’s annual financial and 

public health policy request in 

accordance with DHHS, Office of 

Management and Budget (OMB), and 

Congressional requirements, policies, 

procedures, and regulations; (4) 

maintains liaison with the DHHS, OMB, 

other government organizations, and 

Congress on appropriations and 

financial policy matters; (5) develops 

materials for, and participates in, public 

health policy and financial reviews and 

hearings before DHHS, OMB, and 

Congress; (6) collaborates with other 

parts of CDC, and outside stakeholders, 

in the development and implementation 

of agency-wide financial and public 

health program plans; and (7) provides 

guidance and advice on the 

consolidation of budget and 

performance information as part of 

CDC’s annual budget request. 

Delete the functional statements for 

the Accounting Branch (CAJEB) and the 

Commercial Payment Branch (CAJEE) 

and insert the following: 

Accounting Branch (CAJEB). (1) 

Oversees and provides accounting for 

the Agency; (2) manages accounting 

treatment for CDC on all business 

systems implementations and upgrades 

to current business systems; (3) manages 

all financial audit reviews for FMO and 

conducts risk assessment on internal 

controls; (4) prepares SF 133 Report on 

Budget Execution for CDC 

Appropriation and IDDAs, FACTS I and 

IT Report and Year-End Closing 

Statement (2108 Report), and SF 224 or 

their equivalent and all other required 

financial reports as applicable; (5) 

prepares, analyzes fluctuations, and 

coordinates explanation for differences 

on all required financial statements and 

notes: (6) performs GPRA reporting 

analysis for compliance; (7) ensures 

compliance of Federal and Department 

reporting requirements; (8) coordinates 

accounting policy issues with the 

Department of Health and Human 

Services (DHHS) Office of Financial 

Policy and FMO’s Office of Management 

Services; (9) manages Fund Balance 

with Treasury, including authority, 

disbursements (payroll and nonpayroll), collections, deposit funds and 

budget clearing accounts; (10) prepares 

manual and ADI journal vouchers for 

corrections to the general ledger; (11) 

performs monthly, quarterly, and yearend close out process of the general 

ledger; (12) serves as liaison with the 

Procurements and Grants Office, 

Buildings and Facilities Offices, 

Program Offices, and Budget Execution 

Services on capital asset procedures; 

(13) manages financial accounting for all 

assets for CDC, including real and 

personal property, equipment, land, 

leases, software, personal property, and 

stockpiles; (14) conducts financial and 

inventory reconciliations for all 

applicable assets, including inventory 

such as Vaccine for Children and 

Strategic National Stockpile, real and 

personal property, equipment, leases, 

leasehold improvements, land, and 

others as needed; (15) leads and directs 

grants management activities within 

FMO; (16) provides training and 

assistance to CDC project officers and 

grants management officials on various 

financial management aspects of grants; 

(17) serves as liaison with grantees and 

other operating divisions for financial 

questions/inquiries related to grants; 

(18) manages the process to perform 

grant processing for commitments, 

obligations, advances, disbursements, 

and accruals; (19) manages grants 

transactions, such as vendor set-up, 

establishing sub-accounts, Common 

Accounting Number set-up within the 

Payment Management System (PMS), 

reconciling sync file to PMS, and 

posting files from PMS; (20) conducts 

grant reviews, monitors rates of 

expenditure for existing grant awards, 

and supports Program in grant 

execution; and (21) records undelivered 

order adjustments or obligations as 

needed. 

Commercial Payment Branch (CAJEE). 

(1) Manages all activities, policies, 

quality control, and audit support for 

accounts payable and disbursement 

functions for commercial payments; (2) 

serves as the CDC subject matter expert 

on all financial matters dealing with 

commercial payments; (3) ensures all 

commercial payments are made in 

accordance with applicable Federal 

laws and standards, such as 

Appropriations Law; (4) serves as 

liaison with the Department of Treasury, 

the Centers/Institutes/Offices (CIO’s), as 

well as outside customers, to provide 

financial information and reconcile 

commercial payment issues; (5) 

provides training and advice on 

commercial payment and disbursement 

issues; (6) manages transactions related 

to commercial accounts payable and 

disbursements; (7) completes all 

reconciliations of sub-legers to general 

ledger related to commercial payments; 

(8) compiles and submits a variety of 

cash management and commercial 

reports required by Treasury and 

various outside agencies; (9) responds to 

commercial inquiries for invoices and 

certifies payments; (10) performs 

Quality Control and Quality Assurance 

reviews and participates in internal 

reviews; and (11) assists with 

undelivered order adjustments or 

obligations as needed. 

Delete in its entirety the title and 

function statements for the Grants and 

Asset Management Branch (CAJEK). 

After the functional statements for the 

Budget Execution Branch 6 (CAJES) 

insert the following: 

Travel, IPAC, and International 

Payment Branch (CAJET). (1) Manages 

all activities, policies, quality control, 

and audit support for accounts payable 

and disbursement functions for travel, 

IPAC, and international payments; (2) 

serves as the CDC subject matter expert 

on all financial matters dealing with all 

travel, IPAC, and international 

payments; (3) ensures all travel, IPAC, 

and international payments are made in 

accordance with applicable Federal and 

international laws and standards, such 

as appropriations law; (4) serves as 

liaison with the Department of Treasury, 

the CIOs, as well as outside customers, 

to provide financial information and 

reconcile travel, IPAC, and international 

payment issues; (5) compiles and 

submits a variety of cash management 

and travel reports required by the 

Department of Treasury and various 

other outside agencies; (6) provides 

training and advice on payment, travel 

and disbursement issues; (7) manages 

transactions related to accounts payable, 

such as processing cables, 

reimbursements, IPAC disbursements, 

and payments for Foreign nationals and 

visiting fellows; (8) completes all 

reconciliations of sub-legers to general 

ledger related to travel, IPAC, and 

international payments; (9) responds to 

traveler inquiries for vouchers and 

certifies payments; (10) manages change 

of station payment processing; (11) 

perform quality control and quality 

assurance reviews; (12) provides 

expertise, guidance, oversight, and 

interpretation of policies, laws, rules 

and regulations for all aspects of travel 

procedures and policies at CDC, 

including the use of the automated 

travel system, local travel, domestic and 

foreign temporary duty travel, and 

change of station travel for civil service 

employees, foreign service employees, 

commissioned officers, CDC fellows, 

etc.; (13) communicates and implements 

departmental travel policies; (14) 

manages the administrative aspects of 

travel for the agency, including 

enforcement of travel card policy, 

delegation of authority, distribution of 

cash purchase memos, and approval of 

first-class memos; (15) serves as liaison 

with travel provider for travel contract 

matters; (16) provides the CDC’s 


emcdonald on DSK5VPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 3 / Thursday, January 5, 2012 / Notices 511 

Emergency Operations Center travel 

support; and (17) develops CDC 

conference travel planning and 

reporting for DHHS and Congress. 

Dated: December 22, 2011. 

Sherri A. Berger, 

Chief Operating Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2011–33791 Filed 1–4–12; 8:45 am] 

BILLING CODE 4163–18–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, PAR–11– 

259: Pregnancy in Women with Disabilities. 

Date: January 24, 2012. 

Time: 11 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Priscah Mujuru, RN, MPH, 

DRPH, COHNS, Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 3139, MSC 7770, Bethesda, MD 20892, 

(301) 594–6594, mujurup@mail.nih.gov. 

Name of Committee: Oncology 1—Basic 

Translational Integrated Review Group, 

Cancer Etiology Study Section. 

Date: January 30–31, 2012. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Mandarin Oriental, 1330 

Maryland Avenue SW., Washington, DC 

20024. 

Contact Person: Elaine Sierra-Rivera, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6184, 

MSC 7804, Bethesda, MD 20892, (301) 435– 

1779, riverase@csr.nih.gov. 

Name of Committee: Oncology 2— 

Translational Clinical Integrated Review 

Group, Developmental Therapeutics Study 

Section. 

Date: January 30–31, 2012. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marina del Rey Marriott, 4100 

Admiralty Way, Marina del Rey, CA 90292. 

Contact Person: Sharon K Gubanich, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6214, 

MSC 7804, Bethesda, MD 20892, (301) 408– 

9512, gubanics@csr.nih.gov. 

Name of Committee: Digestive, Kidney and 

Urological Systems Integrated Review Group, 

Clinical, Integrative and Molecular 

Gastroenterology Study Section. 

Date: January 30, 2012. 

Time: 8 a.m. to 7 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, Bethesda, MD 20814. 

Contact Person: Mushtaq A Khan, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2176, 

MSC 7818, Bethesda, MD 20892, (301) 435– 

1778, khanm@csr.nih.gov. 

Name of Committee: Genes, Genomes, and 

Genetics Integrated Review Group, Molecular 

Genetics B Study Section. 

Date: January 30–31, 2012. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Westin Los Angeles Airport Hotel, 

5400 West Century Boulevard, Los Angeles, 

CA 90045. 

Contact Person: Richard A Currie, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5128, 

MSC 7840, Bethesda, MD 20892, (301) 435– 

1219, currieri@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Program 

Project, Proteome Technologies. 

Date: January 30, 2012. 

Time: 1 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Westin Los Angeles Airport 

Hotel, 5400 W Century Boulevard, Los 

Angeles, CA 90045. 

Contact Person: Richard A Currie, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1108, 

MSC 7890, Bethesda, MD 20892, (301) 435– 

1219, currieri@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Chronic 

Fatigue Syndromes. 

Date: January 31–February 1, 2012. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Lynn E Luethke, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5166, 

MSC 7844, Bethesda, MD 20892, (301) 806– 

3323, luethkel@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: December 29, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–33834 Filed 1–4–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Special Pilot 

Clinical Studies in Nephrology and Urology. 

Date: January 12–13, 2012. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Ryan G Morris, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4205, 

MSC 7814 Bethesda, MD 20892, (301) 435– 

1501, morrisr@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Emerging 

Technologies and Training Neurosciences 

Integrated Review Group, Bioengineering of 

Neuroscience, Vision and Low Vision 

Technologies Study Section. 

Date: January 31, 2012. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 


emcdonald on DSK5VPTVN1PROD with NOTICES